Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × TIC10 compound × CNS × Clear all

Status

Withdrawn 4 Terminated 3 Recruiting 3 No longer available 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

3-Iodobenzylguanidine 2 tucatinib 1 rindopepimut 1 pembrolizumab 1 pegfilgrastim 1 paclitaxel-Angiopep-2 conjugate 1 omburtamab I-131 1 mogamulizumab 1 fluorodopa F 18 1 efineptakin alfa 1 avapritinib 1 Vorinostat 1 TIC10 compound 1 Potassium Iodide 1 OKN 007 1 Ketoconazole 1 Ipilimumab 1 Granulocyte Colony-Stimulating Factor 1 Fenretinide 1 Cancer Vaccines 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03134131 2022-03-14

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Jazz Pharmaceuticals

No longer available

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡